Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...
Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...
Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $21 from $18 and keeps a Neutral rating on ...
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...
Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.
TD Cowen analyst Jonna Kim maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price target of ...
Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...
Hims & Hers Health reported its third-quarter results after Monday's closing bell. Here's a look at the details from the ...
It was Donald Trump and Kamala Harris’s last chance to speak directly to the American people who have not yet decided who ...
Hims & Hers Health raised its full-year outlook after it swung to a profit in the third quarter boosted by a tax benefit and consumer demand for weight-loss drugs.
Hims & Hers Health Inc. ($HIMS) rallied nearly 9% in pre-market trading on Tuesday, following the company’s third-quarter ...
The legendary singer-songwriter, who had 25 of her songs reach number one on the Billboard hot country songs chart, was asked ...